

# Naureen Starling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3112028/publications.pdf>

Version: 2024-02-01

120  
papers

7,594  
citations

186209

28  
h-index

54882

84  
g-index

126  
all docs

126  
docs citations

126  
times ranked

12240  
citing authors

#	ARTICLE	IF	CITATIONS
1	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 36-46.	13.9	2,052
2	Colorectal cancer. <i>Lancet</i> , The, 2010, 375, 1030-1047.	6.3	1,318
3	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	6.0	1,199
4	Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2607-2615.	0.8	387
5	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	7.7	187
6	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	7.7	179
7	Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3786-3793.	0.8	155
8	Patients'™ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. <i>Trials</i> , 2016, 17, 17.	0.7	148
9	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
10	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
11	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 183-192.	3.2	79
12	Safety and efficacy of anti-™PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9-9.	0.8	69
13	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
14	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018, 67, 1484-1492.	6.1	59
15	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881628.	1.4	56
16	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 153-163.	2.0	49
17	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-709.	0.8	49
18	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	2.0	47

#	ARTICLE	IF	CITATIONS
19	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	1.5	46
20	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e69-e76.	1.0	44
21	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. <i>European Journal of Cancer</i> , 2019, 121, 40-47.	1.3	43
22	The genomic landscape of oesophagogastric junctional adenocarcinoma. <i>Journal of Pathology</i> , 2013, 231, 301-310.	2.1	42
23	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	3.2	42
24	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 72-82.	2.0	40
25	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. <i>BMC Cancer</i> , 2015, 15, 15.	1.1	35
26	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. <i>Oncotarget</i> , 2016, 7, 12672-12681.	0.8	34
27	Pancreatic neuroendocrine tumors: a review. <i>Future Oncology</i> , 2015, 11, 853-864.	1.1	33
28	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
29	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017, 22, 402-408.	1.9	31
30	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. <i>Oncogene</i> , 2019, 38, 1717-1733.	2.6	29
31	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. <i>Current Cancer Drug Targets</i> , 2010, 10, 799-812.	0.8	28
32	Current and Future Therapies for Advanced Gastric Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 239-250.	1.0	28
33	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02,) Tj ETQq1 1 0.7843 14 rgBT4 Overlo	1.4	27
34	Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. <i>Current Opinion in Oncology</i> , 2004, 16, 385-390.	1.1	27
35	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. <i>Clinical Colorectal Cancer</i> , 2018, 17, 223-230.	1.0	27
36	Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 159-170.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer, 2008, 8, 192.	1.1	25
38	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers, 2019, 11, 1558.	1.7	25
39	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 2021, 70, 1632-1641.	6.1	24
40	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, 2021, 70, 1904-1913.	6.1	24
41	Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5499-5505.	0.8	23
42	Role of erlotinib in the management of pancreatic cancer. Therapeutics and Clinical Risk Management, 2006, 2, 435-445.	0.9	23
43	Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. OncoTargets and Therapy, 2016, Volume 9, 7235-7245.	1.0	22
44	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. Journal of Clinical Oncology, 2021, 39, 102-102.	0.8	20
45	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Critical Reviews in Oncology/Hematology, 2015, 95, 318-336.	2.0	18
46	Colorectal cancer – Authors' reply. Lancet, The, 2010, 376, 331-332.	6.3	17
47	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer, 2016, 16, 112.	1.1	17
48	Targeting deficient DNA damage repair in gastric cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1757-1766.	0.9	16
49	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. Oncologist, 2016, 21, 1502-1508.	1.9	16
50	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology and Evolution, 2021, 5, 1024-1032.	3.4	16
51	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. Cancers, 2019, 11, 736.	1.7	15
52	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the National Cancer Institute, 2021, 113, 88-98.	3.0	15
53	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. Journal of Clinical Oncology, 2016, 34, 154-154.	0.8	15
54	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. European Radiology, 2020, 30, 6702-6708.	2.3	14

#	ARTICLE	IF	CITATIONS
55	POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3615-TPS3615.	0.8	14
56	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. <i>Oncotarget</i> , 2017, 8, 64999-65008.	0.8	14
57	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	0.8	13
58	The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 1443-1453.	1.0	12
59	Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. <i>Cancer Treatment Reviews</i> , 2018, 71, 32-38.	3.4	11
60	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
61	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. <i>Clinical Colorectal Cancer</i> , 2019, 18, 64-71.e1.	1.0	10
62	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.	5.8	10
63	Cetuximab in Previously Treated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, S28-S33.	1.0	9
64	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9
65	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4154-TPS4154.	0.8	9
66	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001–2010. <i>Gastric Cancer</i> , 2016, 19, 1114-1124.	2.7	8
67	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-17.	0.7	8
68	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 201-201.	0.8	8
69	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4120-TPS4120.	0.8	8
70	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. <i>Gastric Cancer</i> , 2014, 17, 621-629.	2.7	7
71	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
72	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 658-658.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 333.	0.8	7
74	Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 613-613.	0.8	7
75	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Therapeutic Advances in Medical Oncology, 2016, 8, 104-112.	1.4	6
76	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. Clinical Colorectal Cancer, 2017, 16, e181-e189.	1.0	6
77	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precision Oncology, 2020, 4, 1152-1162.	1.5	6
78	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. Journal of Clinical Oncology, 2021, 39, 4015-4015.	0.8	6
79	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1159-1167.	1.4	6
80	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878622.	1.4	5
81	Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. Gastroenterology Research and Practice, 2019, 2019, 1-15.	0.7	5
82	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	1.0	5
83	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. Journal of Clinical Oncology, 2020, 38, 218-218.	0.8	5
84	Pharmacotherapy for Oesophagogastric Cancer. Drugs, 2007, 67, 2539-2556.	4.9	4
85	PLATFORM: Planning treatment of oesophago-gastric (OG) cancerâ€”A randomised maintenance therapy trial.. Journal of Clinical Oncology, 2016, 34, TPS187-TPS187.	0.8	4
86	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. Journal of Clinical Oncology, 2018, 36, TPS4139-TPS4139.	0.8	4
87	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC) Tj ETQq1 b8784314 rgBT /Ov		
88	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	4
89	Abstract 258: MicroRNAs as biomarkers of resistance to HER2 inhibition in combination with chemotherapy in gastro-esophageal cancer. , 2020, , .		4
90	Second-line therapy for advanced colorectal carcinoma. Current Oncology Reports, 2005, 7, 173-180.	1.8	3

#	ARTICLE	IF	CITATIONS
91	EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers. <i>Annals of Oncology</i> , 2019, 30, v251-v252.	0.6	3
92	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 401-401.	0.8	3
93	Effect of perioperative FLOT <i>versus</i> ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. <i>BJS Open</i> , 2022, 6, .	0.7	3
94	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. <i>Anticancer Research</i> , 2018, 38, 5943-5949.	0.5	2
95	Clonal diversity of MYC amplification evaluated by fluorescent inÂsitu hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. <i>European Journal of Cancer</i> , 2019, 122, 12-21.	1.3	2
96	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1634.	1.3	2
97	Does shorter duration of chemotherapy worsen survival for elderly patients with colon cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 12-13.	4.3	1
98	Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v201-v202.	0.6	1
99	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16074-e16074.	0.8	1
100	Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 644-644.	0.8	1
101	Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010.. <i>Journal of Clinical Oncology</i> , 2015, 33, 169-169.	0.8	1
102	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS221-TPS221.	0.8	1
103	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. <i>Journal of Clinical Oncology</i> , 2018, 36, 246-246.	0.8	1
104	Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial. , 2018, , .		1
105	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. <i>Journal of Clinical Oncology</i> , 2019, 37, 535-535.	0.8	1
106	P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases. <i>Annals of Oncology</i> , 2020, 31, S134-S135.	0.6	1
107	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel Â± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3686-3694.	3.2	1
108	Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist oncology phase I unit.. <i>Journal of Clinical Oncology</i> , 2013, 31, 45-45.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	0
110	Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts).. Journal of Clinical Oncology, 2015, 33, 188-188.	0.8	0
111	A prospective patient (pt) survey on clinical trials.. Journal of Clinical Oncology, 2015, 33, 707-707.	0.8	0
112	Formulating a surveillance strategy following surgery for oesophagogastric cancer.. Journal of Clinical Oncology, 2015, 33, 153-153.	0.8	0
113	FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors.. Journal of Clinical Oncology, 2015, 33, TPS227-TPS227.	0.8	0
114	Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial. , 2015, , .		0
115	A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.. Journal of Clinical Oncology, 2016, 34, 580-580.	0.8	0
116	Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage. , 2018, , .		0
117	SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. Journal of Clinical Oncology, 2020, 38, TPS471-TPS471.	0.8	0
118	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. Current Oncology, 2022, 29, 2174-2184.	0.9	0
119	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, PR012-PR012.	0.4	0
120	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, A002-A002.	0.4	0